It’s been more than two years since then. Ticketing and live events have survived the pandemic and StubHub is poised to reignite its IPO ambitions in 2024. The Informationreported in April 2024 that StubHub may seek an IPO as soon as late Summer 2024. But in July, the Wall Street Jour...
Upon regulatory approvals, NorthStar will retain exclusive U.S. marketing and distribution rights for I-123 capsules in 100 µCi and 200 µCi formulations. FDA approval is expected in 2023. Corporate development and industry leadership NorthStar is firmly positioned for sustained, ...
CLEVELAND, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2024: Wells Fargo Healthcare Conference: Investor meetings on Thursday, September 5, 20...
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for pat...
Visit HSD at MD&M East, the east coast’s largest Medtech event taking place at the Jacob K. Javits Convention Center in New York, NY. Booth #1470 More info Jun 08-01 TOR ALDEN SPEAKING AT THE FIRST FDANEWS COMBINATION PRODUCT REGULATION CONFERENCE Join Tor Alden at the first FDAnews Co...
HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive bil...
aligning their interests closely with shareholders and underscoring their commitment to the company's success. Collectively, Nuvectis' co-founders bring over 50 years of biotech experience and a proven track record of performance, including spearheading the approval of three drugs, two of which are...
“We are also eagerly looking forward to a Type C meeting in May 2023, which was granted by the U.S. FDA to discuss the opportunity to leverage non-invasive endpoints to support NASH product development and, potentially, for seeking approval for NASH...
Toby McIntosh, managing editor of BNA's "Daily Report for Executives," thought subscribers could benefit from these scans as well... Staff - 《Library Journal》 被引量: 0发表: 2005年 Daily Tax Report BY RAY BEEMAN AND ROBERT CARROLL W hile the current spotlight may be on upcoming ...
Kobel continued, "In 2024, our goal is to make additional strides throughout our pipeline of differentiated gamma delta T cell therapies via a strategic and disciplined approach. Receiving clearance on our IND from the U.S. FDA of TCB-008 in Acute Myeloid Leukemia marks an importa...